Back to Search Start Over

Antigenics cancer vaccine promising in kidney cancer.

Source :
PharmaWatch: Biotechnology; Jul2007, Vol. 6 Issue 7, p6-6, 1/2p
Publication Year :
2007

Abstract

The article reports on the revelation of U.S.-based Antigenics Inc. in its end-of-study results of therapeutic cancer vaccine Oncophage. According to biotechnology firm, its end-of-study results have shown that Oncophage prolongs recurrence-free survival of about 45% in patients with intermediate-risk kidney cancer.

Details

Language :
English
Volume :
6
Issue :
7
Database :
Complementary Index
Journal :
PharmaWatch: Biotechnology
Publication Type :
Report
Accession number :
25688129